Non-Fucosylated Anti-Human CD19 (3649-aFuc) Therapeutic Antibody (CAT#: BioBet-1674ZP) Datasheet

CD19

CD19 molecule

Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.

CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4

As the cell surface receptor of fibroblast growth factor, protein tyrosine kinase plays a vital role in regulating cell proliferation, differentiation, migration and apoptosis and regulating embryonic development. Normal embryonic pattern, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development are required. It plays a vital role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is necessary for normal bone development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylate PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signal cascades. The activation of PLCG1 leads to the production of cell signaling molecules diacylglycerol and inositol 1,4,5-triphosphate. Phosphorylation of FRS2 triggers the recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates the activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and MAP kinase signaling pathways and AKT1 signaling pathway. FGFR2 signal transduction is down-regulated due to ubiquitination, internalization and degradation. Mutations that cause constitutive kinases to activate or impair normal FGFR2 maturation, internalization and degradation can lead to abnormal signaling. Over-expressed FGFR2 promotes the activation of STAT1.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

3649-aFuc

Humanized

Human

The binding affinity of the 3649-3M Fc variant antibody to Fc [gamma] RIIIA and the 3649-aFuc non-fucosylated antibody is much higher than the binding affinity of the fucosylated 3649 antibody.

Refractory B cell precursor Acute lymphoblastic leukemia
Relapsed B cell precursor Acute lymphoblastic leukemia

3649